Adverse events related to COVID-19 vaccines: the need for strengthening pharmacovigilance monitoring systems

Research output: Contribution to journalArticlepeer-review

Authors

  • Sunil Shrestha
  • Januka Khatri
  • Sujyoti Shakya
  • Krisha Danekhu
  • Asmita Priyadarshini Khatiwada
  • Ranjit Sah
  • Bhuvan Kc
  • Saval Khanal
  • Alfonso J. Rodriguez-morales

Colleges, School and Institutes

Abstract

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by a new species of β-coronavirus genus named severe acute respiratory syndrome coronavirus 2. The COVID-19 pandemic, which started in late 2019 and continues as at mid-2021, has caused enormous damage to health and lives globally. The urgent public health need has led to the development of vaccines against COVID-19 in record-breaking time. The COVID-19 vaccines have been widely rolled out for the masses by many countries following approval for emergency use by the World Health Organization and regulatory agencies in many countries. In addition, several COVID-19 vaccine candidates are undergoing clinical trials. However, myths, fears, rumors, and misconceptions persist, particularly in regard to adverse events. In this commentary, we describe the adverse events associated with COVID-19 vaccines and discuss why it is essential to have a functional adverse event monitoring system in this context.

Bibliographic note

Copyright © 2021, The Author(s), under exclusive licence to Springer Nature Switzerland AG

Details

Original languageEnglish
Pages (from-to)376–382
Number of pages7
JournalDrugs & Therapy Perspectives
Volume37
Issue number8
Publication statusPublished - 2 Aug 2021

Sustainable Development Goals